About Sensus Healthcare, Inc. - Common Stock (SRTS)
Sensus Healthcare Inc is a medical technology company that specializes in developing innovative solutions for the treatment of non-melanoma skin cancers and other dermatological conditions. The company focuses on providing non-invasive and effective therapies, particularly through its proprietary Sensus device that utilizes ultrasound technology for the precise targeting of cancerous tissues. In addition to skin cancer treatment, Sensus Healthcare also explores applications in other areas of oncology and dermatology, aiming to improve patient outcomes while minimizing side effects associated with traditional treatment methods. The company's commitment to research and development allows it to drive advancements in medical care, enhancing the quality of life for patients. Read More
Sensus Healthcare (SRTS) beat Q3 2025 earnings estimates despite a revenue dip. The company highlighted a key regulatory win with new CPT codes for its skin cancer treatment technology.
Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, announces financial results for the three and nine months ended September 30, 2025.
Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, today announced that it has been named to TIME’s list of America’s Growth Leaders of 2026, developed in partnership with Statista Inc.
Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, announces that the Centers for Medicare & Medicaid Services (CMS) has published a distinct set of treatment codes specific to the use of superficial radiotherapy (SRT and IG-SRT) for non-melanoma skin cancer (NMSC).
Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, announces the passing of longtime friend of the Company and current Director William “Bill” McCall.
Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, announces the company will report financial results for the third quarter of 2025 on Thursday, November 6, 2025. Management will hold a conference call beginning at 4:30 p.m. Eastern time to review the results, provide a business update and answer questions.
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Sensus (SRTS) To Contact Him Directly To Discuss Their Options
NEW YORK, Sept. 24, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Sensus Healthcare, Inc. (“Sensus” or the “Company”) (NASDAQ: SRTS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, announces that a study published in Dermatologic Therapy demonstrates the safety and efficacy of the Company’s superficial radiotherapy (SRT) technology combined with punch excision to treat keloids.
NEW YORK, Sept. 14, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Sensus Healthcare, Inc. (“Sensus” or the “Company”) (NASDAQ: SRTS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
NEW YORK, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Sensus Healthcare, Inc. (“Sensus” or the “Company”) (NASDAQ: SRTS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Sensus (SRTS) To Contact Him Directly To Discuss Their Options
NEW YORK, Sept. 06, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Sensus Healthcare, Inc. (“Sensus” or the “Company”) (NASDAQ: SRTS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
NEW YORK, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against AVITA Medical, Inc. (NASDAQ:RCEL), Coty Inc. (NYSE:COTY), and Sensus Healthcare, Inc. (NASDAQ:SRTS). Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices. Additional information about each case can be found at the link provided.
NEW YORK, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Sensus Healthcare, Inc. (“Sensus” or the “Company”) (NASDAQ: SRTS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Sensus (SRTS) To Contact Him Directly To Discuss Their Options
NEW YORK, Aug. 29, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Sensus Healthcare, Inc. (“Sensus” or the “Company”) (NASDAQ: SRTS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
NEW YORK, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Sensus Healthcare, Inc. (“Sensus” or the “Company”) (NASDAQ: SRTS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Sensus Healthcare, Inc. (“Sensus” or “the Company”) (NASDAQ: SRTS) for violations of the securities laws.
NEW YORK, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Sensus Healthcare, Inc. (“Sensus” or the “Company”) (NASDAQ: SRTS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
